Ernesto Ruiz Duque, MD
Advanced Heart Failure and Transplant Cardiology · Iowa City, IANPI 1215439708
Payments from drug & device makers
What this record shows
Abbott accounts for 71.1% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2024 at $4,705 and has fallen 82.9% since, to $807 in 2025.
Across 114 payments — averaging $69.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$6K
- Abiomed$2K
- Edwards Lifesciences$178
- Boston Scientific$71
- Lexicon Pharmaceuticals, Inc.$31
- Impulse Dynamics (USA) Inc.$23
- plus $52 from 4 others
Across 25 payments — averaging $17,009 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$382K
- Alnylam Pharmaceuticals Inc.$43K
What the payments were for
- Travel & lodging$4,17352%
- Food & beverage$3,78548%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 88 | $5,655 |
| Abiomed | 13 | $1,947 |
| Edwards Lifesciences | 2 | $178 |
| Boston Scientific | 3 | $71 |
| Lexicon Pharmaceuticals, Inc. | 1 | $31 |
| Impulse Dynamics (USA) Inc. | 1 | $23 |
| Itamar Medical Inc | 1 | $21 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $13 |
| Sanofi | 1 | $13 |
| Cvrx, Inc. | 3 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$2,405
- Impella$1,513
- CARDIOMEMS$1,496
How this compares
Too few advanced heart failure and transplant cardiology providers in Iowato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 62 | $785,024 |
| VyndamaxTafamidis | 27 | $569,839 |
| AdempasRiociguat | 35 | $488,588 |
| UptraviSelexipag | 24 | $426,012 |
| JardianceEmpagliflozin | 301 | $268,364 |
| EntrestoSacubitril/Valsartan | 300 | $260,985 |
| EliquisApixaban | 210 | $158,082 |
| FarxigaDapagliflozin Propanediol | 98 | $65,746 |
| XareltoRivaroxaban | 20 | $25,668 |
| Sildenafil Citrate | 80 | $14,740 |
| Sirolimus | 40 | $11,642 |
| Bumetanide | 97 | $4,515 |
| VascepaIcosapent Ethyl | 14 | $4,511 |
| Potassium Chloride | 163 | $3,324 |
| Torsemide | 145 | $3,182 |
Paid to pharmacies, not to this prescriber.
Other advanced heart failure and transplant cardiology in Iowa City
- Linda CadaretIowa City$14K
- Pavida PachariyanonIowa City$11K
- Serkan BekturIowa City$5K
- Paulino AlvarezIowa City$2K
- Alexandros BriasoulisIowa City$725
- Kelly Ann Light McGroaryIowa City$440
- Ily Kristine YumulIowa City$247
- Frances JohnsonIowa City$111
- Mansour EsmaeiliIowa City$26
- Akrivi ManolaDes Moines$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.